Systems hematology: Simon Haas receives Heisenberg professorship
In March 2024, Dr. Simon Haas took up a Heisenberg professorship in systems hematology at the Berlin Institute of Health at Charité (BIH). Haas, who leads a lab within the joint research focus of the BIH, Charité – Universitätsmedizin Berlin, and the Max Delbrück Center, is seeking to understand interactions between stem cells and immune cells. In a groundbreaking discovery, he found a previously unknown protective mechanism that prevents blood cancer from developing from stem cells. The professorship is funded by the German Research Foundation (DFG) and aims to enable outstanding early career scientists to continue their research careers.
In March 2024, Dr. Simon Haas received funding commitment from the German Research Association (DFG) for a Heisenberg professorship in systems hematology at the Berlin Institute of Health at Charité (BIH). Haas, who leads a lab within the joint research focus of the BIH, Charité – Universitätsmedizin Berlin, and the Max Delbrück Center, is seeking to understand interactions between stem cells and immune cells. In a groundbreaking discovery, he found a previously unknown protective mechanism that prevents blood cancer from developing from stem cells. The professorship is funded by the German Research Foundation (DFG) and aims to enable outstanding early career scientists to continue their research careers. After the five-year funding period, the BIH will make the professorship permanent.
Leukemia, a blood cancer, occurs when immature immune cells stop developing but keep dividing and eventually inundate the blood. There, they encounter mature and active immune cells that either recognize and kill the cancer cells or let them escape. While this process occurs regularly in the human body, the complex interplay between defective cells, the immune system, and other factors determines whether emerging cancer cells are eliminated or develop into a malignant cancer. Understanding this interplay is essential for finding new approaches to the treatment and prevention of blood diseases like leukemia.
How cancer and immune cells communicate
This is the focus of the research being carried out by Haas, a molecular biologist and head of the BIH’s Systems Hematology, Stem Cells & Precision Medicine Group. He and his group members, who are experts in single-cell analysis, are developing the technique further so that it not only produces individual snapshots of cells, but also captures the interactions and communication between the immune cells and cancer cells. Haas and his team are located at the Berlin Institute for Medical Systems Biology of the Max Delbrück Center (MDC-BIMSB), which offers outstanding technical infrastructure for their work. The scientists want to decode the signals that the cells exchange during their encounter, discerning the stage of development they are currently in and how the binding impacts the cells: Does it activate the immune cell? Does it kill the cancer cell?
“Over the next few years, we plan to further develop and refine our novel technologies – not only to deepen our understanding of cancer pathology, but also to enable these technologies to be used as precision tools in clinical practice,” explains Haas. “We don’t just want to identify cancer cells earlier and more accurately. It’s also about prediction: Which individuals are at risk of developing leukemia and can we ideally prevent it from breaking out?”
For this project and his excellent scientific track record, Haas has now been awarded a Heisenberg professorship in systems hematology at the BIH, which will be funded by the German Research Foundation (DFG). He has led the BIH’s Systems Hematology, Stem Cells & Precision Medicine Group since November 2020.
“The Heisenberg Program supports outstanding scientists, so it was no surprise to us that Simon was selected for this honor,” says Prof. Christopher Baum, Chair of the BIH Board of Directors and Chief Translational Research Officer of Charité. “His excellent scientific work combines basic research and application-oriented studies. Simon and his team are thus strengthening the translational network that comprises the BIH, Charité, and the MDC. The common goal is to improve patients’ quality of life.”
---------------------------
About Simon Haas
Simon Haas studied molecular cell biology, biochemistry, and molecular biosciences at Heidelberg University, Imperial College London, and the German Cancer Research Center (DKFZ). He received his PhD from DKFZ and Heidelberg University in 2016. Haas conducted research at DKFZ, the Massachusetts Institute of Technology (MIT) and Harvard. From 2016 to 2020 he worked as a junior group leader at the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM). In 2000 he moved to Berlin, where he is a group leader at the Berlin Institute of Health at Charité (BIH), Charité – Universitätsmedizin Berlin, and the Berlin Institute for Medical Systems Biology of the Max Delbrück Center (MDC-BIMSB). Haas has received numerous awards and grants, including an ERC Starting Grant, the Otto Schmeil Prize, the Young Investigator Award of the German Stem Cell Network, and the Lisec-Artz Prize.
Further information about Haas’s research can be found at https://www.bihealth.org/en/research/research-group/systems-hematology-stem-cells-precision-medicine.
About the Heisenberg program
Since 1978, the Heisenberg Program has been part of the funding portfolio of the German Research Association (DFG). In addition to Heisenberg fellowships, positions, and rotation positions, the program offers the option of a Heisenberg professorship. Heisenberg professorships enable outstanding researchers to establish themselves as professors at a German university. To this end, the DFG provides funding for a fixed-term professorship (W2 or W3) for a period of up to five years. The host university must make a binding declaration that it will permanently incorporate the Heisenberg professorship into its budget after the end of the DFG funding period if the interim evaluation by the DFG (after three years of funding) and an evaluation carried out by the university during the same period (optional) lead to a positive result. Further details: https://www.dfg.de/en/research-funding/funding-opportunities/programmes/individual/heisenberg .
---------------------------
Contact
Press Office
Berlin Institute of Health at Charité (BIH)
Konstanze Pflüger: +49 (0)30 450 543 343
pressestelle-bih@bih-charite.de
www.bihealth.org
---------------------------
About the Berlin Institute of Health at Charité (BIH)
The mission of the Berlin Institute of Health at Charité (BIH) is medical translation: transferring biomedical research findings into novel approaches to personalized prediction, prevention, diagnostics and therapies and, conversely, using clinical observations to develop new research ideas. The aim is to deliver relevant medical benefits to patients and the population at large. As the translational research unit within Charité, the BIH is also committed to establishing a comprehensive translational ecosystem – one that places emphasis on a system-wide understanding of health and disease and that promotes change in the biomedical translational research culture. The BIH was founded in 2013 and is funded 90 percent by the Federal Ministry of Education and Research (BMBF) and 10 percent by the State of Berlin. The founding institutions, Charité – Universitätsmedizin Berlin and the Max Delbrück Center, were independent member entities within the BIH until 2020. Since 2021 the BIH has been integrated into Charité as its so-called third pillar. The Max Delbrück Center is now the Privileged Partner of the BIH.
Weitere Informationen:
https://www.bihealth.org/en/notices/systemmedizin-in-der-haematologie-foerderzusage-fuer-heisenberg-professur-an-simon-haas
Die semantisch ähnlichsten Pressemitteilungen im idw
